BriaCell Therapeutics Corp. announced positive survival data from its Phase 2 study of Bria-IMT™ combined with checkpoint inhibitors in metastatic breast cancer patients. The treatment regimen exceeded the current standard of care, Trodelvy® (sacituzumab govitecan-hziy), in overall survival for hormone receptor-positive (HR+) patients and demonstrated comparable survival to Trodelvy® in triple-negative breast cancer (TNBC) patients. Notably, no treatment discontinuations related to Bria-IMT™ were observed.
This data holds significant promise for patients with advanced breast cancer, particularly those with HR+ tumors, who currently face limited treatment options and often experience shorter survival times. The improved survival observed with Bria-IMT™ suggests a potential paradigm shift in the treatment landscape for these patients. Furthermore, the comparable efficacy to Trodelvy® in TNBC, coupled with the reported safety profile, positions Bria-IMT™ as a potentially valuable alternative therapy.
In the Phase 2 study, 25 of the 37 patients treated with the pivotal Phase 3 formulation of Bria-IMT™ had HR+ breast cancer. These patients demonstrated a median overall survival of 17.3 months, surpassing the 14.4 months observed with Trodelvy® in a similar patient population. In patients with TNBC, the Bria-IMT™ regimen yielded a median overall survival of 11.4 months, comparable to the 11.8 months seen with Trodelvy®. Importantly, these results were achieved in a heavily pre-treated patient population with a median of six prior lines of therapy.
These findings underscore the potential of Bria-IMT™ to become a leading treatment option for advanced breast cancer. The ongoing Phase 3 study, with overall survival as the primary endpoint, will be crucial for confirming these promising results and paving the way for potential regulatory approval and commercialization. The positive safety profile observed so far further strengthens the case for Bria-IMT™ as a viable and potentially transformative therapy in this challenging disease setting.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
